LIFESPIN-GMBH
13.12.2021 09:02:20 CET | Business Wire | Press release
Lifespin GmbH, a deep data company currently developing a proprietary AI-based health testing platform to measure quantitative metabolic data in patient samples, has secured €2.5M bridge financing to fuel the company’s continued product development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211213005059/en/
The Lifespin platform is based on mapping metabolomics for human health and translating that data into health information that can be deployed in a wide range of pharmaceutical, research, and clinical settings. Lifespin’s health diagnostics software will be applicable in the broader healthcare space ranging from diagnostics to patient stratification and personalized medicine, as well as supporting the drug discovery process.
“We are very excited about Lifespin’s growth trajectory with a platform solution which can be accessed by collaborating clinical laboratories and drug discovery partners and scale globally via our cloud solutions,” said Lifespin’s CEO, Dr. Ali Tinazli.
The bridge financing will be used to continue the development of the first diagnostics panel for neurological diseases such as multiple sclerosis and Parkinson’s disease, some of which cannot be addressed with legacy laboratory-based methods. The first commercial test of the differential diagnostics panel will be covering early stages of multiple sclerosis. The panel will be further expanded with other neurological indications over time.
“Lifespin’s new software-based approach to digitally capture, compare and analyze human metabolomes will open up a new and exciting field, complementary to existing health diagnostics,” said Robert Wieland, Managing Director of Wieland Capital and Lifespin’s lead investor.
Lifespin expects to begin fundraising for a Series A in 2022 to fund its first product introductions and to support expanding its business operations to the United States.
# # #
Lifespin (www.lifespin.ai ) is a deep data company that maps human health based on metabolomics. Lifespin’s advisory board consists of key opinion leaders such as James Rothman (Nobel Laureate in Physiology/Medicine, Sterling Professor of Cell Biology, Yale University, New Haven, CT USA) and numerous industry veterans. We have standardized the baseline for human health and can detect distinct deviations caused by diseases. A pathogenesis impacts metabolism, causing specific changes in the presence and quantity of metabolites. Our proprietary technology platform quantitatively captures individual metabolomes, i.e., up to hundreds of metabolite concentrations with a single Nuclear Magnet Resonance (NMR) measurement. Lifespin is building a proprietary in-house biobank with currently 200,000 human blood samples and performing quantitative in-house measurements of metabolomes for systematic mapping across health conditions. Our constantly growing proprietary database of digitized metabolic profiles enables the analysis of billions of metabolic relationships. Digital metabolic profiles enable differential diagnosis for the early detection of health conditions, staging of diseases, monitoring of treatment success and personalized medicine. Our first regulatory approved Software-as-IVD will be for the early differential diagnosis of multiple sclerosis and is expected in 2022. This will be followed by other tests for the detection of neurological, cancer, and inflammatory diseases. Our cloud-based business model is built on our proprietary Software-as-a-Service (SaaS) platform for diagnostics and health information and is globally scalable.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211213005059/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom